TABLE A1.
Postdiscontinuation Anticancer and Immunotherapy in All Treated Participants
Therapy | Lenvatinib + Pembrolizumab + Chemotherapy (n = 443), No. (%) | Chemotherapy (n = 437), No. (%) |
---|---|---|
Received any subsequent systemic anticancer therapy | 202 (46) | 273 (62) |
Subsequent systemic therapy by type | ||
Chemotherapy | 196 (44) | 255 (58) |
Any PD-1/PD-L1 | 20 (5) | 83 (19) |
Any VEGF | 85 (19) | 126 (29) |
Other | 93 (21) | 108 (25) |
Other immunotherapy | 2 (1) | 8 (2) |
Abbreviation: VEGF, vascular endothelial growth factor.